Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Zhang, Le-Ping  [Clear All Filters]
2023
Zhang F, Hu G-H, Zhang L-P, Xu L-P, Suo P, Wang Y, Bai L, Liu K-Y, Zhang X-H, Huang X-J, et al. Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study. Leuk Lymphoma. 2023:1-6.
2020
Bai L, Cheng Y-F, Lu A-D, Suo P, Wang Y, Zuo Y-X, Yan C-H, Wu J, Jia Y-P, Sun Y-Q, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020;91:106333.
2019
Xue Y-J, Suo P, Huang X-J, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Kong J, Zhang X-H, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukae. Br J Haematol. 2019.
2018
Xue Y-J, Cheng Y-F, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Sun Y-Q, Suo P, Chen Y-H, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2018.
Wang Y-Z, Hao L, Chang Y, Jiang Q, Jiang H, Zhang L-P, He L-L, Yuan X-Y, Qin Y-Z, Huang X-J, et al. A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. Leuk Res. 2018;72:12-19.